Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review

125I-Anti-malondialdehyde-modified low-density lipoprotein monoclonal antibody

Kam Leung  1
In: Molecular Imaging and Contrast Agent Database (MICAD) [Internet]. Bethesda (MD): National Center for Biotechnology Information (US); 2004.
[updated ].
Affiliations
Free Books & Documents
Review

125I-Anti-malondialdehyde-modified low-density lipoprotein monoclonal antibody

Kam Leung.
Free Books & Documents

Excerpt

Apolipoprotein E (apoE) is essential for the normal catabolism of triglyceride-rich lipoprotein chylomicrons (lipoprotein particles) (1). Oxidation of low-density lipoprotein (LDL) generates a number of highly reactive short chain-length aldehydic fragments of oxidized fatty acids capable of conjugating with lysine residues of apoliprotein B and other proteins. Oxidized LDL is present in atherosclerotic lesions and is essential for formation of foam cells in atherosclerotic plaques. During atherogenic conditions, depositions of lipids and extracellular matrix proteins on the endothelial cell surfaces of the aorta and cells lead to the development of atherosclerotic plaques (2), which may erode and rupture. MDA2 is a murine monoclonal antibody (mAb) to malondialdehyde-lysine epitopes of MDA-LDL and other oxidatively modified proteins but not to normal LDL (3). Tsimikas and colleagues (4-6) have studied 125I-MDA2 for imaging atherosclerotic plaques in small animals.

PubMed Disclaimer

References

    1. Eichner J.E., Dunn S.T., Perveen G., Thompson D.M., Stewart K.E., Stroehla B.C. Apolipoprotein E polymorphism and cardiovascular disease: a HuGE review. . Am J Epidemiol. 2002;155(6):487–95. - PubMed
    1. Libby P., Ridker P.M., Maseri A. Inflammation and atherosclerosis. . Circulation. 2002;105(9):1135–43. - PubMed
    1. Palinski W., Yla-Herttuala S., Rosenfeld M.E., Butler S.W., Socher S.A., Parthasarathy S., Curtiss L.K., Witztum J.L. Antisera and monoclonal antibodies specific for epitopes generated during oxidative modification of low density lipoprotein. . Arteriosclerosis. 1990;10(3):325–35. - PubMed
    1. Tsimikas S. Noninvasive imaging of oxidized low-density lipoprotein in atherosclerotic plaques with tagged oxidation-specific antibodies. . Am J Cardiol. 2002;90(10C):22L–27L. - PubMed
    1. Tsimikas S., Palinski W., Halpern S.E., Yeung D.W., Curtiss L.K., Witztum J.L. Radiolabeled MDA2, an oxidation-specific, monoclonal antibody, identifies native atherosclerotic lesions in vivo. . J Nucl Cardiol. 1999;6(1 Pt 1):41–53. - PubMed

LinkOut - more resources